Aradigm Corp. (ARDM) Stock Quote

Detailed Quote for Aradigm Corp. (ARDM)

close 52 Week Information

52 Week High

March 3, 2011

Close: 0.245

52 Week Low

January 12, 2012

Close: 0.085

Today

5d

1m

3m

1y

more

Last Price
0.121

Change $
0.009

Change %
6.92%

Tick
N/A

Bid
0.12

Bid Size
5,000

Ask
0.185

Ask Size
5,000

Open
0.125

High
0.125

Low
0.121

Prev Close
0.13

Last Trade
3:55

Volume
15 k

52 Wk Hi
0.245

52 Wk Low
0.085

Market Cap
24.11 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
199,281,216

EPS (TTM)
-0.05

PE Ratio
N/A

close Exchange Information Listed On OTC Bulletin Board Consolidated (OTCBB) Exchange
OTCBB

News and Media for Aradigm Corp. (ARDM)

Sector News | Topic News

News for ARDM

Wed, Feb 08, 2012

7:00 AM

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13 - Business Wire

Thu, Jan 05, 2012

1:06 PM

Aradigm to Present at Biotech Showcase 2012 on January 9 - Business Wire

Wed, Dec 07, 2011

7:00 AM

Aradigm Selects Pulmaquin(tm) for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations - Business Wire

Mon, Jun 06, 2011

9:00 AM

Baseline Demand & Emerging Nations Drive Growth -- Insight on MultiCell Technologies, Inc. and Aradigm Corporation - Marketwire

Thu, Jun 02, 2011

9:00 AM

New Demand & Necessity Buoy Industry -- Insight on MultiCell Technologies, Inc. and Aradigm Corporation - Marketwire

Fri, Nov 20, 2009

4:47 PM

AllPennyStocks.com Announces November 23rd to November 27th U.S. Penny Stocks 2 Watch (LPIH.OB, ARDM.OB) - Accesswire

4:47 PM

AllPennyStocks.com Announces November 23rd to November 27th U.S. Penny Stocks 2 Watch (LPIH.OB, ARDM.OB) - Accesswire

More News for ARDM >>

Tags for Aradigm Corp.

Research stocks or mutual funds related to Aradigm Corp. by keywords or tags. Find companies that have a similar focus to ARDM. The keywords below have been associated to ARDM by either user submission or electronic means.

patent lawyers pulmonary specialist pharmaceutical market generic pharmaceutical trademark name Chronic obstructive pulmonary disease dupont pharmaceuticals copyright law respiratory pharma marketing pharmaceutical software pharma manufacturing pharma license pfizer pharmaceutical company trademark protection generic products drug delivery pharmaceutical cro pharma companies patent ideas intellectual property policy restrictive lung disease pharmaceutical distributors pharma in licensing intellectual property attorney music copyright law pharmaceutical development pharmaceutical reports pharma product development Drugs copyright laws pharmaceutical industry news intellectual property law pharmaceutical manufacturing software intellectual property attorneys intellectual property copyright pharmaceutical manufacturing intellectual property theft valuation of intellectual property intellectual property software patent law firm contract pharmaceutical trademarks pharmaceutical industry intellectual property law firms intellectual property law firm patent database intellectual property cases clinical trials europe patent attorney

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.